Treatment with human growth hormone–releasing hormone (GHRH) for 20 weeks had favorable effects on cognitive function in a randomized controlled trial of healthy older adults and those with mild cognitive impairment (MCI).
Compared with placebo, daily subcutaneous injections of tesamorelin (Egrifta, Theratechnologies, Inc) were associated with improvement on tests of executive function and possibly memory, the study team reports in an article published online August 6 in Archives of Neurology.
